NCT04275713View on ClinicalTrials.gov

Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

May 22, 2020

Primary Completion Date

June 11, 2024

Study Completion Date

November 8, 2024

Conditions
Cervical Cancer
Interventions
DRUG

Metformin

Metformin is an oral antidiabetic drug

DRUG

Cisplatin

Cisplatin 40 mg/m2 given intravenously once a week, maximum 6 cycles

Trial Locations (1)

0379

Oslo University Hospital, Oslo

All Listed Sponsors
lead

Oslo University Hospital

OTHER

NCT04275713 - Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC | Biotech Hunter | Biotech Hunter